sharecast

{{ storiesRelated.title }}

Frank Prenesti Sharecast News
25 Aug, 2022 08:34 25 Aug, 2022 08:34

AstraZeneca's Lynparza approved in Japan

AstraZeneca

10,292.00p

16:49 14/11/24
1.46%
148.00p

AstraZeneca and MSD's Lynparza has been approved in Japan for the treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence, the companies said on Thursday.

FTSE 100

8,071.19

16:49 14/11/24
n/a
n/a

FTSE 350

4,459.02

16:38 14/11/24
n/a
n/a

FTSE All-Share

4,417.25

16:54 14/11/24
n/a
n/a

Pharmaceuticals & Biotechnology

19,794.96

16:38 14/11/24
0.96%
187.95

The approval by Japan’s Ministry of Health, Labour, and Welfare was based on results from the OlympiA Phase III trial.

In the trial, Lynparza demonstrated a “statistically significant and clinically meaningful improvement” in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus a placebo.

Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival, reducing the risk of death by 32% versus placebo, AstraZeneca said in a statement.

Reporting by Frank Prenesti at Sharecast.com

contador